Merck logo

Merck

Last updated January 31, 2026
124
Innovation Areas
5,362
Inventors
47
Collaborations

Viral fusion protein inhibitors: MerckRecent Research Landscape

Uncontrolled viral replication leads to severe respiratory pathology and high hospitalization costs. These molecular scaffolds target specific viral entry mechanisms to arrest infection cycles.

What technical problems is Merck addressing in Viral fusion protein inhibitors?

Cross species viral entry failure

(12)evidences

The keywords highlight a need to address multiple distinct viral strains and families simultaneously. Preventing infection across diverse viral targets overcomes the limitation of narrow-spectrum efficacy and rapid viral escape.

Persistent herpesvirus replication

(2)evidences

Inadequate suppression of viral entry and replication cycles. Effective inhibition prevents chronic infection persistence and cellular damage.